Uterine Balloon Treatment for Heavy Period Bleeding.

This study has been completed.
Information provided by:
Ethicon, Inc.
ClinicalTrials.gov Identifier:
First received: September 19, 2005
Last updated: January 13, 2009
Last verified: January 2009
The purpose of this research is to determine the proportion of women who achieve permanent cessation of bleeding after Uterine Balloon Therapy (UBT) for the treatment of heavy uterine bleeding.

Condition Intervention Phase
Device: Uterine Balloon Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Evaluation of Uterine Balloon Therapy System for Menorrhagia

Resource links provided by NLM:

Further study details as provided by Ethicon, Inc.:

Primary Outcome Measures:
  • Incidence of post-procedure amenorrhea in women treated with uterine balloon therapy. [ Time Frame: 6 and 12 mo ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Post-procedure bleeding levels [ Time Frame: 2 and 3 yrs ] [ Designated as safety issue: No ]
  • Effect of post-procedure curettage on bleeding patterns, post-operative discharge and post-operative pain. [ Time Frame: 2 and 3 yrs ] [ Designated as safety issue: No ]
  • System utility as indicated by equipment events that require intervention. [ Time Frame: perioperative ] [ Designated as safety issue: No ]

Enrollment: 250
Study Start Date: March 2003
Study Completion Date: September 2008
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Uterine Balloon Therapy with post procedure curettage
Device: Uterine Balloon Therapy
UBT with post procedure curettage
Other Name: with post procedure curettage
Experimental: 2
Uterine Balloon Therapy without post-procedure curettage
Device: Uterine Balloon Therapy
UBT without post procedure curettage
Other Name: without post procedure curettage

Detailed Description:
This study was also designed to determine the effect of a post procedure curettage on bleeding patterns and post-operative discharge and pain.

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female at least 30 years of age who is premenopausal and for whom childbearing is complete.
  • Excessive menstrual bleeding documented by a diary score of at least 150.
  • Have documented 3 months failed medical therapy or either a) contraindicated for or b) refused medical therapy.
  • Have an anatomically normal uterine cavity sounding at least 4cm, but not greater than 12cm.
  • Have a normal pap smear and no unexplained abnormal pap smears within 1 year of the procedure.
  • Agree not to switch from hormonal to non-hormonal contraception or vice versa during or just prior to the study.
  • Agree to use reliable contraception throughout the study.
  • Freely agree to participate in the study, including all study related procedures and evaluations, and document this agreement by signing informed consent documentation.

Exclusion Criteria:

  • Active pelvic inflammatory disease (PID) or recurrent chronic PID.
  • Active genital or urinary tract infection at the time of the procedure.
  • History of malignancy of the reproductive system within 5 years of the procedure or have ever had malignancy of the endometrium.
  • Endometrial neoplasia, determined by endometrial biopsy taken within 6 months of procedure.
  • Cavity distorting submucous myoma(s) determined by preoperative hysterogram, hysteroscopy, or transvaginal sonography within 6 months of the procedure.
  • Previous endometrial ablation procedure.
  • Previous uterine surgeries (such as full thickness myomectomy, subserosal myomectomy, uterine reconstruction, or any surgery in which thinning of the uterine musculature could occur) except for low transverse caesarean section.
  • Pregnant or desirous of future pregnancy.
  • Taken endometrial suppression medication, except for oral contraceptives, within 3 months of the procedure.
  • Concurrent open or laparoscopic surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00215618

Sponsors and Collaborators
Ethicon, Inc.
Principal Investigator: Charles T Cash, MD Oakwood Hospital and Medical Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David Robinson MD, Ethicon Inc
ClinicalTrials.gov Identifier: NCT00215618     History of Changes
Other Study ID Numbers: 2003-010 
Study First Received: September 19, 2005
Last Updated: January 13, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Genital Diseases, Female
Menstruation Disturbances
Pathologic Processes
Uterine Diseases
Uterine Hemorrhage

ClinicalTrials.gov processed this record on May 26, 2016